Global Patent Index - EP 1263452 A4

EP 1263452 A4 20061220 - METHODS AND COMPOSITIONS FOR GENERATING ANGIOSTATIN

Title (en)

METHODS AND COMPOSITIONS FOR GENERATING ANGIOSTATIN

Title (de)

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR HERSTELLUNG VON ANGIOSTATIN

Title (fr)

PROCEDES ET COMPOSITIONS PERMETTANT DE PRODUIRE DE L'ANGIOSTATINE

Publication

EP 1263452 A4 20061220 (EN)

Application

EP 01907105 A 20010208

Priority

  • US 0104021 W 20010208
  • US 50039700 A 20000208

Abstract (en)

[origin: WO0158921A2] The invention provides methods of generating angiostatin <i>in vitro</i> comprising contacting plasminogen with a plasminogen activator and a sulfhydryl donor or contacting plasmin with a sulfhydryl donor. The invention also provides a method of treating angiogenic diseases by administering to an animal suffering from such a disease a sulfhydryl donor, a plasminogen activator, or a combination of a sulfhydryl donor and a plasminogen activator. The invention further comprises a composition for generating angiostatin comprising a sulfhydryl donor and a plasminogen activator. The invention also provides a container holding a sulfhydryl donor and/or a plasminogen activator, said container having a label thereon instructing administration of the sulfhydryl donor and/or plasminogen activator to an animal suffering from an angiogenic disease. The invention further provides plasminogen fragments whose N-terminal amino acid is the same as that of plasmin and whose C-terminal amino acid is located in kringle 5 and which inhibit angiogenesis, antibodies which bind selectively to these fragments, methods and kits for using the antibodies, methods and materials for making the fragments by recombinant DNA techniques, and a method of treating an angiogenic disease comprising administering an effective amount of one of the fragments. Finally, the invention provides a method of treating an angiogenic disease comprising administering a transgene coding for one of the fragments.

IPC 1-7

A61K 38/00; C07K 14/00

IPC 8 full level

G01N 33/53 (2006.01); A61K 31/198 (2006.01); A61K 31/401 (2006.01); A61K 38/00 (2006.01); A61K 38/16 (2006.01); A61K 38/46 (2006.01); A61K 38/48 (2006.01); A61K 38/49 (2006.01); A61K 38/51 (2006.01); A61K 48/00 (2006.01); A61P 9/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 43/00 (2006.01); C07K 1/22 (2006.01); C07K 14/46 (2006.01); C07K 16/18 (2006.01); C07K 16/40 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 9/68 (2006.01); C12N 15/09 (2006.01); C12P 21/02 (2006.01); G01N 33/573 (2006.01)

CPC (source: EP)

A61K 31/198 (2013.01); A61K 31/401 (2013.01); A61K 38/164 (2013.01); A61K 38/166 (2013.01); A61K 38/484 (2013.01); A61K 38/49 (2013.01); A61K 38/51 (2013.01); A61P 9/00 (2017.12); A61P 35/00 (2017.12); A61P 35/04 (2017.12); A61P 43/00 (2017.12); C07K 16/40 (2013.01); C12N 9/6435 (2013.01); C12Y 304/21007 (2013.01); G01N 33/573 (2013.01); A61K 48/00 (2013.01); G01N 2333/968 (2013.01)

C-Set (source: EP)

  1. A61K 38/51 + A61K 38/484 + A61K 38/063
  2. A61K 38/164 + A61K 2300/00
  3. A61K 38/166 + A61K 2300/00
  4. A61K 38/484 + A61K 2300/00
  5. A61K 38/49 + A61K 2300/00
  6. A61K 38/51 + A61K 2300/00
  7. A61K 38/51 + A61K 38/484 + A61K 31/40
  8. A61K 38/51 + A61K 38/484 + A61K 31/195
  9. A61K 38/484 + A61K 38/164 + A61K 38/063
  10. A61K 38/484 + A61K 38/164 + A61K 31/40
  11. A61K 38/484 + A61K 38/164 + A61K 31/195
  12. A61K 38/164 + A61K 38/063
  13. A61K 38/164 + A61K 31/40
  14. A61K 38/164 + A61K 31/195

Citation (search report)

  • [X] WO 9815574 A1 19980416 - UNIV NORTHWESTERN [US], et al
  • [A] EP 0366033 A2 19900502 - SQUIBB & SONS INC [US]
  • [A] WO 8803030 A1 19880505 - MOSCATELLI DAVID A [US], et al
  • [A] VOLPERT O V ET AL: "Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 98, no. 3, 1 August 1996 (1996-08-01), pages 671 - 679, XP002223374, ISSN: 0021-9738
  • [A] HOURANI B T ET AL: "INHIBITION OF S-91 MOUSE MELANOMA METASTASES AND GROWTH BY D-PENICILLAMINE", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 21, no. 5, 1969, pages 434 - 438, XP008010946, ISSN: 0023-6837
  • [A] FRIESS ET AL: "Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 113, no. 3, September 1997 (1997-09-01), pages 904 - 913, XP005688578, ISSN: 0016-5085
  • See references of WO 0158921A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0158921 A2 20010816; WO 0158921 A3 20020214; WO 0158921 A9 20020314; AU 3492601 A 20010820; CA 2400497 A1 20010816; EP 1263452 A2 20021211; EP 1263452 A4 20061220; JP 2004508006 A 20040318

DOCDB simple family (application)

US 0104021 W 20010208; AU 3492601 A 20010208; CA 2400497 A 20010208; EP 01907105 A 20010208; JP 2001558068 A 20010208